# Exploring the Anti-Cervical Cancer Effect and Hepatotoxicity Risk of Gossypol Based on Untargeted Metabolomics and Network Toxicology

**Authors:** Jinyan Li, Parwen Parhat, Yinglan Ma, Liuqian Peng, Min Li

PMC · DOI: 10.3390/ph19030377 · Pharmaceuticals · 2026-02-27

## TL;DR

This study investigates how gossypol affects cervical cancer in mice and its potential to cause liver damage, using metabolomics and network toxicology.

## Contribution

The study introduces a novel integration of untargeted metabolomics and network toxicology to explore gossypol's anti-cancer effects and hepatotoxicity mechanisms.

## Key findings

- Gossypol significantly suppressed subcutaneous cervical cancer tumor growth in nude mice.
- Gossypol's hepatotoxicity involves multiple targets like MTOR and pathways such as apoptosis and HIF-1 signaling.
- Untargeted metabolomics identified 9 key metabolites and 1464 total metabolites in liver tissues.

## Abstract

Objectives: This research sought to examine the impact of gossypol on cervical cancer tumors that have been transplanted subcutaneously in nude mice, as well as the associated risk of liver damage and its underlying mechanisms. Methods: A subcutaneous cervical cancer tumor model was established in nude mice using the cell suspension inoculation method. Tumor volume and morphological changes in various organs were observed, and the serum concentrations of IL-6, IL-10, and TNF-α were assessed. Protein expression was analyzed using Western blotting. Untargeted metabolomics was employed to identify differential metabolites in mouse liver tissues. Network toxicology was utilized to pinpoint common targets associated with gossypol and hepatotoxicity, followed by KEGG and GO enrichment analyses. Molecular docking was conducted to preliminarily explore the mechanisms underlying gossypol-induced liver injury. Results: Gossypol significantly suppressed the development of subcutaneous cervical cancer tumors in immunodeficient mice. The Western blotting technique results revealed that increasing doses of gossypol led to a reduction in the expression levels of PIK3R2, GRB2, and MAPK1, compared to the model group (p < 0.05). Untargeted metabolomics revealed 1464 metabolites, from which 9 distinct metabolites were selected for further analysis. Network toxicology results indicated that the hepatotoxicity-related targets of gossypol included MTOR, TNF, CASP3, BCL2L1, and BCL2. KEGG analysis suggested that the toxic mechanisms may be linked to pathways involved in malignancy, the HIF-1 signaling pathway, proteoglycans in cancer, apoptosis, and others. Conclusions: Gossypol demonstrates a significant therapeutic effect against cervical cancer; however, its hepatotoxicity risk, mediated through multiple targets and pathways, requires further investigation.

## Linked entities

- **Genes:** PIK3R2 (phosphoinositide-3-kinase regulatory subunit 2) [NCBI Gene 5296], GRB2 (growth factor receptor bound protein 2) [NCBI Gene 2885], MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], TNF (tumor necrosis factor) [NCBI Gene 7124], CASP3 (caspase 3) [NCBI Gene 836], BCL2L1 (BCL2 like 1) [NCBI Gene 598], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596]
- **Chemicals:** gossypol (PubChem CID 3503), IL-6 (PubChem CID 165368475), IL-10 (PubChem CID 146070)
- **Diseases:** cervical cancer (MONDO:0002974)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Grb2 (growth factor receptor bound protein 2) [NCBI Gene 14784] {aka Ash}, Pik3r2 (phosphoinositide-3-kinase regulatory subunit 2) [NCBI Gene 18709] {aka p85beta}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Bcl2l1 (BCL2-like 1) [NCBI Gene 12048] {aka Bcl(X)L, Bcl-XL, Bcl2l, BclX, bcl-x, bcl2-L-1}, Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}
- **Diseases:** liver injury (MESH:D017093), Cervical Cancer (MESH:D002583), Tumor (MESH:D009369), liver damage (MESH:D056486)
- **Chemicals:** Gossypol (MESH:D006072)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028656/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13028656/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028656/full.md

---
Source: https://tomesphere.com/paper/PMC13028656